See more : Hot Chili Limited (HCH.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Lexaria Bioscience Corp. (LEXX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexaria Bioscience Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tai Shing Electronics Components Corporation (3426.TWO) Income Statement Analysis – Financial Results
- Hang Zhou Iron & Steel Co.,Ltd. (600126.SS) Income Statement Analysis – Financial Results
- Triton American Energy Corp. (TRAE) Income Statement Analysis – Financial Results
- Oriental Land Co., Ltd. (OLCLF) Income Statement Analysis – Financial Results
- Bear Electric Appliance Co.,Ltd. (002959.SZ) Income Statement Analysis – Financial Results
Lexaria Bioscience Corp. (LEXX)
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.28K | 226.21K | 255.40K | 722.74K | 384.54K | 222.61K | 433.29K | 63.64K | 40.72K | 14.70K | 1.10M | 1.36M | 1.13M | 362.47K | 421.96K | 900.79K | 253.15K | 20.31K | 20.31K |
| Cost of Revenue | 4.82K | 31.50K | 71.84K | 175.35K | 99.38K | 22.89K | 25.19K | 29.75K | 45.62K | 29.88K | 795.20K | 783.27K | 667.86K | 273.62K | 548.32K | 912.75K | 124.91K | 93.32K | 93.32K |
| Gross Profit | 459.46K | 194.71K | 183.56K | 547.39K | 285.17K | 199.72K | 408.10K | 33.89K | -4.90K | -15.18K | 302.25K | 574.49K | 465.91K | 88.86K | -126.37K | -11.96K | 128.24K | -73.01K | -73.01K |
| Gross Profit Ratio | 98.96% | 86.07% | 71.87% | 75.74% | 74.16% | 89.72% | 94.19% | 53.25% | -12.03% | -103.26% | 27.54% | 42.31% | 41.09% | 24.51% | -29.95% | -1.33% | 50.66% | -359.55% | -359.55% |
| Research & Development | 2.36M | 3.67M | 1.84M | 1.26M | 387.07K | 555.73K | 492.86K | 54.19K | 9.02K | 146.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.85M | 3.06M | 5.72M | 4.97M | 3.57M | 3.13M | 6.02M | 1.63M | 1.01M | 1.49M | 1.27M | 561.89K | 678.09K | 466.67K | 458.04K | 475.34K | 1.01M | 121.44K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 204.28K | 515.36K | 489.06K | 209.03K | 185.46K | 276.56K | 8.19K | 3.47K | 40.92K | 559.00 | 930.00 | 4.11K | 20.07K | 20.07K | 0.00 |
| SG&A | 3.85M | 3.06M | 5.72M | 4.97M | 3.77M | 3.64M | 6.51M | 1.84M | 1.20M | 1.76M | 8.19K | 565.35K | 719.01K | 467.23K | 458.97K | 479.45K | 1.03M | 141.51K | 35.14K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 112.75K | 60.55K | 2.31K | -886.00 | 4.60K | -22.66K | 0.00 | 14.04K | 6.40K | 0.00 | 8.21K | 1.28K | 148.38K | -2.99K | 0.00 |
| Operating Expenses | 6.21M | 6.73M | 7.57M | 6.23M | 4.27M | 4.26M | 7.01M | 1.90M | 1.21M | 1.91M | 8.19K | 579.40K | 725.41K | 474.00K | 467.18K | 480.72K | 1.18M | 138.53K | 35.14K |
| Cost & Expenses | 6.22M | 6.76M | 7.64M | 6.41M | 4.37M | 4.28M | 7.03M | 1.92M | 1.26M | 1.94M | 803.40K | 1.36M | 1.39M | 747.61K | 1.02M | 1.39M | 1.30M | 231.85K | 35.14K |
| Interest Income | 14.31K | 43.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 94.00 | 4.09K | 18.09K | 6.12K | 6.12K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.02K | 2.25K | 31.54K | 267.36K | 246.61K | 278.73K | 167.32K | 160.12K | 857.58K | 4.71K | 21.91K | 21.91K |
| Depreciation & Amortization | 76.15K | 145.40K | 146.91K | 147.60K | 146.09K | 60.55K | 2.31K | 1.49K | 619.00 | -22.66K | 1.52M | 456.60K | 370.62K | 122.16K | 342.13K | 453.12K | 148.38K | 81.76K | 40.44K |
| EBITDA | -5.68M | -6.39M | -6.52M | -5.58M | -4.00M | -4.10M | -6.61M | -1.92M | -1.26M | -1.95M | 294.06K | -35.30K | 442.73K | 111.12K | -236.15K | -244.37K | -414.37K | -891.03K | -129.78K |
| EBITDA Ratio | -1,222.75% | -2,824.23% | -2,835.72% | -977.11% | -982.78% | -1,752.23% | -1,522.76% | -2,922.37% | -2,983.84% | -13,269.46% | 26.79% | 33.27% | 9.80% | -72.55% | -59.58% | 37.67% | -356.22% | 730.49% | 26.11% |
| Operating Income | -5.75M | -6.53M | -7.38M | -5.69M | -3.89M | -3.96M | -6.60M | -1.86M | -1.22M | -1.93M | 294.06K | -4.90K | -259.50K | -552.46K | -753.67K | -898.09K | -1.05M | -489.66K | -35.14K |
| Operating Income Ratio | -1,239.16% | -2,888.50% | -2,891.05% | -786.85% | -1,012.10% | -1,779.43% | -1,523.29% | -2,924.71% | -2,985.36% | -13,115.30% | 26.79% | -0.36% | -22.89% | -152.42% | -178.61% | -99.70% | -414.83% | -2,411.28% | -173.02% |
| Total Other Income/Expenses | -55.52K | -178.50K | -764.61K | 1.52M | 0.00 | -228.06K | -8.97K | -6.02K | -34.70K | -55.06K | -355.23K | -246.61K | -276.22K | -278.73K | 0.00 | 7.05K | -73.27K | -565.19K | -473.12K |
| Income Before Tax | -5.81M | -6.71M | -7.38M | -4.16M | -4.08M | -4.16M | -6.61M | -1.93M | -1.28M | -1.98M | -1.87M | -251.51K | -538.23K | -552.46K | -753.67K | -971.35K | -1.05M | -211.54K | -75.58K |
| Income Before Tax Ratio | -1,251.12% | -2,967.41% | -2,891.05% | -576.16% | -1,062.20% | -1,868.03% | -1,525.36% | -3,031.89% | -3,136.82% | -13,489.80% | -170.50% | -18.52% | -47.47% | -152.42% | -178.61% | -107.83% | -416.69% | -1,041.70% | -372.16% |
| Income Tax Expense | 0.00 | 0.00 | -114.33K | -1.66M | -54.29K | 39.62K | -8.97K | -54.17K | -60.23K | -181.23K | 294.06K | 246.61K | 278.73K | 167.32K | -94.00 | 7.14K | 1.04K | 574.84K | 40.59K |
| Net Income | -5.80M | -6.66M | -7.27M | -2.50M | -4.03M | -4.20M | -6.60M | -1.87M | -1.21M | -1.77M | -1.87M | -251.51K | -538.23K | -552.46K | -753.57K | -978.49K | -1.06M | -508.26K | -75.72K |
| Net Income Ratio | -1,248.25% | -2,946.36% | -2,846.28% | -346.50% | -1,048.08% | -1,885.83% | -1,522.97% | -2,937.31% | -2,983.38% | -12,042.58% | -170.50% | -18.52% | -47.47% | -152.42% | -178.59% | -108.63% | -417.10% | -2,502.87% | -372.89% |
| EPS | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| EPS Diluted | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| Weighted Avg Shares Out | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
| Weighted Avg Shares Out (Dil) | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp....
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November 25, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce...
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% respectively, and in blood sugar, by 11.13% and 3.35% respectively. DehydraTECH-semaglutide compositions with...
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has engaged a contract...
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has received lead clinical site...
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms provides the following glucagon-like peptide-1 ("GLP-1") industry...
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has...
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body weight results from the recently completed animal study WEIGHT-A24-1 (the "Study").
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under...
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of...
Source: https://incomestatements.info
Category: Stock Reports